GENINUS Inc. (KOSDAQ:389030)

Market Cap	209.12B +367.9%
Revenue (ttm)	8.81B +31.4%
Net Income	-12.80B
EPS	-383.22
Shares Out	33.35M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	673,031
Average Volume	1,354,724
Open	5,950.00
Previous Close	6,050.00
Day's Range	5,900.00 - 6,480.00
52-Week Range	1,080.00 - 6,480.00
Beta	1.12
RSI	78.32
Earnings Date	Mar 24, 2026

About GENINUS

GENINUS Inc., a bioinformation analysis company, engages in the research and development, manufacture, and sale of genome analysis solutions in South Korea, the United States, and Asia. It offers tarhet and biomarker discovery; AI digital pathology; single cell analysis; and spatial and in-situ transcriptomics services; and SPACEINSIGHT, a cutting-edge cloud based integrated analysis platform. It serves hospitals, pharmaceutical companies, and researchers. The company was founded in 2018 and is headquartered in Seoul, South Korea.

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2018
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 389030

Financial Performance

In 2024, GENINUS's revenue was 6.46 billion, a decrease of -7.35% compared to the previous year's 6.97 billion. Losses were -12.27 billion, 26.7% more than in 2023.